Display options
Cite
Liu XM, Huang JC, Wang GD, et al. Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome. Int J Clin Exp Med. 2014;7(8):2343-6
Liu, X. M., Huang, J. C., Wang, G. D., Lan, S. H., Wang, H. S., Pan, C. W., Zhang, J. P., & Cai, X. H. (2014). Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome. International journal of clinical and experimental medicine, 7(8), 2343-6.
Liu, Xi-Ming, et al. "Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome." International journal of clinical and experimental medicine vol. 7,8 (2014): 2343-6.
Liu XM, Huang JC, Wang GD, Lan SH, Wang HS, Pan CW, Zhang JP, Cai XH. Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome. Int J Clin Exp Med. 2014 Aug 15;7(8):2343-6. eCollection 2014. PMID: 25232433; PMCID: PMC4161593.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2014 Aug 15;7(8):2343-6. eCollection 2014.

Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome.

International journal of clinical and experimental medicine

Xi-Ming Liu, Jin-Cheng Huang, Guo-Dong Wang, Sheng-Hui Lan, Hua-Song Wang, Chang-Wu Pan, Ji-Ping Zhang, Xian-Hua Cai

Affiliations

  1. Department of Orthopaedics, Wuhan General Hospital of Guangzhou Command Wuhan 430070, China.
  2. Department of Orthopaedics, The Second People's Hospital of Yichang 443000 Hubei, China.
  3. Department of Orthopaedics, The People's Hospital of Tuanfeng 438000 Hubei, China.

PMID: 25232433 PMCID: PMC4161593

Abstract

This study aims to investigate the clinical efficacy of Dextran 40 plus dexamethasone on the prevention of fat embolism syndrome (FES) in high-risk patients with long bone shaft fractures. According to the different preventive medication, a total of 1837 cases of long bone shaft fracture patients with injury severity score (ISS) > 16 were divided into four groups: dextran plus dexamethasone group, dextran group, dexamethasone group and control group. The morbidity and mortality of FES in each group were analyzed with pairwise comparison analysis. There were totally 17 cases of FES and 1 case died. The morbidity of FES was 0.33% in dextran plus dexamethasone group and significantly lowers than that of other groups (P < 0.05). There was no significant difference among other groups (P > 0.05). Conclusion from our data is dextran 40 plus dexamethasone can effectively prevent long bone shaft fractures occurring in high-risk patients with FES.

Keywords: Fat embolism syndrome; dexamethasone; dextran 40; fractures; prevention

References

  1. Arch Surg. 1974 Jan;108(1):70-4 - PubMed
  2. Leg Med (Tokyo). 2008 Jan;10(1):26-30 - PubMed
  3. Injury. 2006 Oct;37 Suppl 4:S59-67 - PubMed
  4. Chest. 1992 Nov;102(5):1323-7 - PubMed
  5. Can J Surg. 2009 Oct;52(5):386-93 - PubMed
  6. Crit Care Med. 2003 Apr;31(4 Suppl):S329-36 - PubMed
  7. Am J Orthop (Belle Mead NJ). 2002 Sep;31(9):507-12 - PubMed
  8. J Anesth. 2003;17(3):186-9 - PubMed
  9. J Bone Joint Surg Br. 1987 Jan;69(1):128-31 - PubMed
  10. Lancet. 1989 Jun 3;1(8649):1271 - PubMed
  11. Acta Anaesthesiol Sin. 2002 Jun;40(2):71-9 - PubMed
  12. Injury. 2012 May;43(5):608-12 - PubMed
  13. J Bone Joint Surg Br. 1970 Nov;52(4):732-7 - PubMed
  14. Arthritis Rheum. 1997 Nov;40(11):2055-64 - PubMed
  15. J Trauma. 1978 Jan;18(1):23-6 - PubMed
  16. Injury. 2004 Mar;35(3):309-17 - PubMed
  17. Int J Crit Illn Inj Sci. 2013 Jan;3(1):64-8 - PubMed
  18. Injury. 2006 Oct;37 Suppl 4:S3-7 - PubMed
  19. Injury. 2006 Oct;37 Suppl 4:S68-73 - PubMed

Publication Types